

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Serno, et al.

Serial No.: Continuing Application of U.S. Serial No. 10/122,694

Title: Imidazotriazinone-Containing Compositions for Nasal Administration

MAIL STOP Patent Application
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying modified form PTO-1449.

Copies of the cited references are not enclosed; since they were submitted with an Information Disclosure Statement for related application, U.S. Serial No. 10/122,694.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,



Susan M. Pellegrino

Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation
400 Morgan Lane
West Haven, CT 06516
Telephone: (203) 812-6450
Facsimile: (203) 812-6459

Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office				Serial No.		Art Unit		Filing Date 03/30/04		Atty. Docket No. Le A 35 249C1		
INFORMATION DISCLOSURE CITATION						Applicant(s) Serno, et al.								
U.S. PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (MM/DD/YY)	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	U1	6	3	6	2	1	7	8	03/26/02	Niewohner, et al.	514	218	07/21/00	
	U2	6	0	1	8	0	4	6	01/25/00	Ohashi, et al.	546	62	01/29/98	
	U3	4	6	0	2	0	9	9	07/22/86	Roger Parker	549	479	09/16/82	
FOREIGN PATENT DOCUMENTS														
*		DOCUMENT NO.							DATE (DD/MM/YY)	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F1	0	4	6	3	7	5	6	02/01/92	EP				
	F2	9	4	2	8	9	0	2	22/12/94	WO				
	F3	9	6	3	2	0	0	3	17/10/96	WO				
	F4	9	7	0	3	9	8	5	06/02/97	WO				
	F5	0	9	6	7	2	1	4	29/12/99	EP				
	F6	0	0	0	0	1	9	9	06/01/00	WP				
	F7	0	9	9	2	2	4	0	12/04/00	EP				
	F8	9	9	1	5	1	7	7	01/04/99	WO				
	F9	2	3	1	5	6	7	3	11/02/98	GB				
	F10	9	9	2	4	4	3	3	20/05/99	WO				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)														
	R1	Murray, K., "Phosphodiesterase V _A Inhibitors," DN&P, <u>6</u> : 150-156 (April 1993)												
	R2	Rajfer, J., Aronson, W., Bush, P., Dorey, F., Ignarro, L., "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission," New England J. of Med., <u>326</u> : 90-94 (Jan. 1992)												
	R3	XP-001119414, Sommer, F., Engelmann, U., "Vardenafil Bayer Yakuhin," Curr. Opin. In Invest. Drugs, <u>3</u> (4): 607-613 (2002).												
EXAMINER										DATE CONSIDERED				
<p><small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>														